

b) a fragment of an extracellular domain of (a),

wherein said extracellular domain and said fragment bind CD30.

cont 8 39. A purified CD30-L polypeptide, wherein said polypeptide is a fragment of a protein selected from the group consisting of:

- a) the murine CD30-L protein of SEQ ID NO:6;
 - b) the murine CD30-L protein of SEQ ID NO:19;
 - c) the human CD30-L protein of SEQ ID NO:8; and
 - d) the human CD30-L protein of SEQ ID NO:23;
- wherein said fragment binds CD30.

REMARKS


This amendment is submitted in order to place the subject application in better condition for examination. Each amendment and new claim is fully supported by the application as filed.

The title as amended corresponds to the designation employed in the specification, for the subject cytokine. The remaining amendments to page 1 insert and update information on related applications.

Support for new claims 32-38 is found on page 16, line 20, to page 17, line 15, of the present specification. Further support for claims 32-38, and support for claim 39, is found on page 4, lines 15-18; page 7, lines 10-20 and 31-33; page 11, line 32, through page 12, line 19; and page 35, line 34, through page 36, line 1.

Claims 27-39 are now pending in the subject application.

Respectfully submitted,



Kathryn A. Anderson
Registration No. 32,172

Immunex Corporation
51 University Street
Seattle, Washington 98101
(206) 587-0430